These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 17461001)

  • 1. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.
    Preen DB; Calver J; Sanfilippo FM; Bulsara M; Holman CD
    Aust N Z J Public Health; 2007 Apr; 31(2):120-6. PubMed ID: 17461001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?
    Calver J; Sanfilippo F; Preen D; Bulsara M
    Aust N Z J Public Health; 2007 Dec; 31(6):533-9. PubMed ID: 18081573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
    McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
    BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
    Donnelly M; Haby MM; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):592-601. PubMed ID: 15298581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
    Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
    J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
    Mac Avin M; Teeling M; Bennett KE
    BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of long-term ADHD medication use in Australian children.
    Efron D; Mulraney M; Sciberras E; Hiscock H; Hearps S; Coghill D
    Arch Dis Child; 2020 Jun; 105(6):593-597. PubMed ID: 31937570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.
    Stevenson RD; Wolraich ML
    Pediatr Clin North Am; 1989 Oct; 36(5):1183-97. PubMed ID: 2677938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of prescription stimulant for Attention Deficit Hyperactivity Disorder in Aboriginal children and adolescents: a linked data cohort study.
    Ghosh M; Holman CD; Preen DB
    BMC Pharmacol Toxicol; 2015 Dec; 16():35. PubMed ID: 26646429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study.
    Boland F; Galvin R; Reulbach U; Motterlini N; Kelly D; Bennett K; Fahey T
    BMC Pediatr; 2015 Sep; 15():118. PubMed ID: 26357902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design.
    Raman SR; Marshall SW; Haynes K; Gaynes BN; Naftel AJ; Stürmer T
    Inj Prev; 2013 Jun; 19(3):164-70. PubMed ID: 23143347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention deficit hyperactivity disorder, combined type: better executive function performance with longer-term psychostimulant medication.
    Vance AL; Maruff P; Barnett R
    Aust N Z J Psychiatry; 2003 Oct; 37(5):570-6. PubMed ID: 14511085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.
    Senior HE; McKinlay L; Nikles J; Schluter PJ; Carmont SA; Waugh MC; Epps A; Lloyd O; Mitchell GK
    BMC Pediatr; 2013 May; 13():89. PubMed ID: 23710976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care.
    Morkem R; Patten S; Queenan J; Barber D
    J Atten Disord; 2020 Jan; 24(2):301-308. PubMed ID: 28748725
    [No Abstract]   [Full Text] [Related]  

  • 20. Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants.
    Mittal S; Boan AD; Kral MC; Lally MD; van Bakergem K; Macias MM; LaRosa A
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):81-86. PubMed ID: 31621385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.